Top image: Performing at Inwood Hill Park, NYC
SCIENCE CONSULTING
Lab of Dr. Parnia at NYU
08/2020 to present: With the lab of Dr. Sam Parnia and the Mütter Museum in Philadelphia, I am developing programming on demystifying death. Overall, we believe that there is a need to demystify death not just from a scientific perspective, but from a philosophical, cultural, and artistic perspectives as well. This program is an ambitious, holistic one to place death and its science on the forefront.
08/2020 to present: With the lab of Dr. Sam Parnia and the Mütter Museum in Philadelphia, I am developing programming on demystifying death. Overall, we believe that there is a need to demystify death not just from a scientific perspective, but from a philosophical, cultural, and artistic perspectives as well. This program is an ambitious, holistic one to place death and its science on the forefront.
Hive Health
07/2020 to 09/2020: As a freelance medical writer, I helped develop a reactive digital application that provides an overview of the client's cardiovascular clinical trial program. This app was meant to be used by Medical Science Liaisons (MSLs) when engaging with healthcare professionals.
07/2020 to 09/2020: As a freelance medical writer, I helped develop a reactive digital application that provides an overview of the client's cardiovascular clinical trial program. This app was meant to be used by Medical Science Liaisons (MSLs) when engaging with healthcare professionals.
Phase Five Communications
04/2018 to 02/2020: As an Associate Medical Director with Phase Five Communications - a global medical education company - I was involved in a variety of projects. Specifically, I
04/2018 to 02/2020: As an Associate Medical Director with Phase Five Communications - a global medical education company - I was involved in a variety of projects. Specifically, I
- Developed webinars, key opinion leaders (KOL) video series, speaker decks, symposia materials, for above-branded and branded education for three Pfizer biosimilar assets on the commercial side: TRAZIMERA, RUXIENCE, ZIRABEV and contributed to strategic planning for pre-launch and launch activities. The indications spanned breast cancer, NHL, CLL, and solid tumors.
- For Pfizer medical affairs, developed content for biosimilars Nivestym for supportive care in oncology.
- For Novavax, I developed gap analyses, publication plans, abstracts, posters, and publications for the company's assets using novel recombinant vaccine technology for RSV, Ebola, and influenza.
- For Novartis, I supported post-launch materials for novel drugs for chronic myelogenous leukemia (CML), acute myeloid leukemia (AML) and melanoma. For this account, I created content, liaised with clients and KOLs, and created summary decks to advise future strategy.
CURE Epilepsy
11/2020 – present: Using the team science principles that were employed for infantile spasms (below), I am developing a publication on a simialr initiative for post-traumatic epilepsies (PTE).
10/2018 – 10/2020: Infantile spasms (IS) is a devastating epilepsy syndrome that typically begins in the first year of life. Symptoms consist of stereotypical spasms, developmental delay and an abnormal EEG pattern known as hypsarrhythmia.
11/2020 – present: Using the team science principles that were employed for infantile spasms (below), I am developing a publication on a simialr initiative for post-traumatic epilepsies (PTE).
10/2018 – 10/2020: Infantile spasms (IS) is a devastating epilepsy syndrome that typically begins in the first year of life. Symptoms consist of stereotypical spasms, developmental delay and an abnormal EEG pattern known as hypsarrhythmia.
- With CURE, I developed a publication a unique method to fund scientific discoveries called the "team science" method.
- This initiative brought together an interdisciplinary group of investigators who would have not otherwise have collaborated to find transformative therapies for IS.
- The published paper is here.
Centers for Disease Control
03/2019-11/2019: I worked on two projects with the CDC:
03/2019-11/2019: I worked on two projects with the CDC:
- Translating educational materials from Spanish to English. These materials were on the following topics: alternative therapies for epilepsy, febrile seizures, caregiver burnout, and basic concepts of epilepsy
- A study looking at the effect of social media on conversations among persons with epilepsy.
Boston Strategic Partners
10/2016-03/2018: I worked as a consultant with Boston Strategic Partners - a global life-science consulting firm with comprehensive clinical, scientific, and business skills providing a multitude of high-value services to clients.
Additional projects at BSP:
10/2016-03/2018: I worked as a consultant with Boston Strategic Partners - a global life-science consulting firm with comprehensive clinical, scientific, and business skills providing a multitude of high-value services to clients.
- At BSP, my engagements focused primarily on the firm’s Medical Communications and Health Economics practice.
- My responsibilities included developing abstracts, posters, manuscripts, articles, and analysis plans for a broad range of client needs. I worked on a project on ZULRESSO™. (brexanolone) Injection, which eventually got approval from the FDA for its use in postpartum depression (PPD). This is the first and only drug indicated specifically for PPD.
- Kingeter AK, Raghunathan K, Munson SH, Hayashida DK, Zhang X, Iyengar S, Bunke M, Shaw AD. Association between albumin administration and survival in cardiac surgery: a retrospective cohort study. Can J Anaesth. 2018. 65(11):1218-1227. Link here.
- Shaw AD, Mythen MG, Shook D, Hayashida DK, Zhang X, Skaar JR, Iyengar S, Munson SH. Pulmonary artery catheter use in adult patients undergoing cardiac surgery: a retrospective, cohort study. Perioper Med (Lond). 2018; 7:24. Link here.
Additional projects at BSP:
- Assessed the impact of hepatorenal syndrome to facilitate the launch of client’s product.
- Developed materials for two clients’ new medications in preparation for FDA approval.
- Developed a budget impact model for sublingual DSUVIA™ - a noninvasive option to deliver opioids in a medically supervised setting.
- Developed abstracts to understand perioperative nurse preferences towards fibrin sealants with regards to ease of use and operating room (OR) efficiency.